Current and prospective applications of exosomal microRNAs in pulmonary fibrosis (Review)

Int J Mol Med. 2022 Mar;49(3):37. doi: 10.3892/ijmm.2022.5092. Epub 2022 Jan 28.

Abstract

Pulmonary fibrosis (PF) is a chronic, progressive, irreversible and life‑threatening lung disease. However, the pathogenesis and molecular mechanisms of this condition remain unclear. Extracellular vesicles (EVs) are structures derived from the plasma membrane, with a diameter ranging from 30 nm to 5 µm, that play an important role in cell‑to‑cell communications in lung disease, particularly between epithelial cells and the pulmonary microenvironment. In particular, exosomes are a type of EV that can deliver cargo molecules, including endogenous proteins, lipids and nucleic acids, such as microRNAs (miRNAs/miRs). These cargo molecules are encapsulated in lipid bilayers through target cell internalization, receptor‑ligand interactions or lipid membrane fusion. miRNAs are single‑stranded RNA molecules that regulate cell differentiation, proliferation and apoptosis by degrading target mRNAs or inhibiting translation to modulate gene expression. The aim of the present review was to discuss the current knowledge available on exosome biogenesis, composition and isolation methods. The role of miRNAs in the pathogenesis of PF was also reviewed. In addition, emerging diagnostic and therapeutic properties of exosomes and exosomal miRNAs in PF were described, in order to highlight the potential applications of exosomal miRNAs in PF.

Keywords: exosomes; extracellular vesicles; microRNA; pathogenesis; pulmonary fibrosis.

Publication types

  • Review

MeSH terms

  • Exosomes* / metabolism
  • Extracellular Vesicles* / metabolism
  • Humans
  • MicroRNAs* / metabolism
  • Pulmonary Fibrosis* / pathology
  • RNA, Messenger / genetics

Substances

  • MicroRNAs
  • RNA, Messenger

Grants and funding

The present study was supported by the Project of The Social Development of Zhenjiang City of China (grant no. SH2020047).